[go: up one dir, main page]

WO1989007598A3 - Procede ameliore de preparation d'inhibiteurs trans-6-[2-(pyrrol substitue-1-yl)alkyle]pyran-2-one de synthese de cholesterol - Google Patents

Procede ameliore de preparation d'inhibiteurs trans-6-[2-(pyrrol substitue-1-yl)alkyle]pyran-2-one de synthese de cholesterol Download PDF

Info

Publication number
WO1989007598A3
WO1989007598A3 PCT/US1989/000719 US8900719W WO8907598A3 WO 1989007598 A3 WO1989007598 A3 WO 1989007598A3 US 8900719 W US8900719 W US 8900719W WO 8907598 A3 WO8907598 A3 WO 8907598A3
Authority
WO
WIPO (PCT)
Prior art keywords
trans
pyran
oxo
improved process
pyrrol
Prior art date
Application number
PCT/US1989/000719
Other languages
English (en)
Other versions
WO1989007598A2 (fr
Inventor
Donald Eugene Butler
Carl Francis Deering
Alan Millar
Thomas Norman Nanninga
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1989007598(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU33496/89A priority Critical patent/AU621874B2/en
Priority to KR1019970702620A priority patent/KR0137884B1/ko
Priority to KR1019970702618A priority patent/KR0123813B1/ko
Priority to KR1019970702617A priority patent/KR970011579B1/ko
Priority to KR1019970702619A priority patent/KR970011462B1/ko
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of WO1989007598A2 publication Critical patent/WO1989007598A2/fr
Priority to KR89701946A priority patent/KR970011578B1/ko
Publication of WO1989007598A3 publication Critical patent/WO1989007598A3/fr
Priority to DK199001970A priority patent/DK175135B1/da
Priority to FI904118A priority patent/FI94958C/fi
Priority to NO903667A priority patent/NO177566C/no
Priority to FI941550A priority patent/FI93958C/fi
Priority to NO941725A priority patent/NO177706C/no
Priority to NO943057A priority patent/NO177423C/no
Priority to NO951075A priority patent/NO180119C/no
Priority to NO963245A priority patent/NO302296B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)

Abstract

On a mis au point un procédé amélioré de préparation de trans-6-[2-(pyrrol substitué-1-yl) alkyle]pyran-2-ones au moyen d'une nouvelle synthèse, permettant de transformer 1,6-heptadiène-4-ol en huit opérations, en produits voulus. On a également mis au point un procédé amélioré de préparation de (2R-trans) et trans-(U)-5-(4-fluoro-phényle)-2-(1-méthylèthyle)-N,4-diphényl-1-[2-(têtrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)éthyle]-1H-pyrrole-3-carboxamide au moyen d'une nouvelle synthèse, permettant de transformer 4-méthyl-3-oxo-N-phénylpentanamide en huit opérations, en le produit voulu, ou dans un autre mode de réalisation de transformer 4-fluoro-alpha-[2-méthyl-1-oxopropyle]-gamma-oxo-N,beta-diphénylbenzènebutaneamide en une étape en le produit voulu. On a, en outre, mis au point un procédé de préparation de (2R-trans)-5-(4-flurophényle)-2-(1-méthyléthyle)-N,4-diphényle-1-[2-(têtrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)éthyle]-1H-pyrrole-3-carboxamide, à partir de (R)-4-cyano-3-[[(1,1-diméthyléthyle)diméthylsilyle]oxy]acide butanoïque, ainsi que d'autres intermédiaires de valeur utilisés dans les procédés.
PCT/US1989/000719 1988-02-22 1989-02-22 Procede ameliore de preparation d'inhibiteurs trans-6-[2-(pyrrol substitue-1-yl)alkyle]pyran-2-one de synthese de cholesterol WO1989007598A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU33496/89A AU621874B2 (en) 1988-02-22 1989-02-22 Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis
KR1019970702620A KR0137884B1 (ko) 1988-02-22 1989-02-22 콜레스테롤 합성 억제제인 트란스-6-[2-(치환-피롤-1-일)알킬] 피란-2-온의 개량된 제조 방법
KR1019970702618A KR0123813B1 (ko) 1988-02-22 1989-02-22 콜레스테롤 합성 억제제인 트란스-6-[2-(치환 피롤-1-일)알킬]피란-2-온의 개량된 제조 방법
KR1019970702617A KR970011579B1 (ko) 1988-02-22 1989-02-22 콜레스테롤 합성 억제제인 트란스-6-[2-(치환 피롤-1-일)알킬]피란-2-온의 개량된 제조방법
KR1019970702619A KR970011462B1 (ko) 1988-02-22 1989-02-22 콜레스테롤 합성 억제제인 트란스-6-[2-(치환 피롤-1-일)알킬]피란-2-온의 개량된 제조 방법
KR89701946A KR970011578B1 (en) 1988-02-22 1989-10-23 Improved process for trans-6-£2-(substituted-pyrrol-1-yl)alkyl|pyran-2-one inhibitors of cholesterol synthesis
DK199001970A DK175135B1 (da) 1988-02-22 1990-08-17 Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese
FI904118A FI94958C (fi) 1988-02-22 1990-08-20 Parannettu menetelmä trans-6-/2-(substituoitu pyrrol-1-yyli)alkyyli/pyran-2-onien valmistamiseksi
NO903667A NO177566C (no) 1988-02-22 1990-08-21 Nye 1,3-dioksan-derivater
FI941550A FI93958C (fi) 1988-02-22 1994-04-05 Parannettu menetelmä trans-5-(4-fluorifenyyli)-2-(1-metyylietyyli)-N,4-difenyyli-1-(2-(tetrahydro-4-hydroksi-6-okso-2H-pyran-2-yyli)etyyli) -1H-pyrroli-3-karboksamidin valmistamiseksi
NO941725A NO177706C (no) 1988-02-22 1994-05-09 Forbedret fremgangsmåte for fremstilling av trans-6-[2- (substituert-pyrrol-yl) alkylÅ pyran-2-on-inhibitorer for kolesterolsyntese
NO943057A NO177423C (no) 1988-02-22 1994-08-18 Forbedret fremgangsmåte for fremstilling av trans-6-[2-(substituert-pyrrol-yl)alkylÅpyran-2-on-inhibitorer for kolesterolsyntese
NO951075A NO180119C (no) 1988-02-22 1995-03-21 Utgangsmaterialer for fremstilling av trans-6-£2-(substituert-pyrrol-yl)alkyl|pyran-2-on-inhibitorer for kolesterolsyntese
NO963245A NO302296B1 (no) 1988-02-22 1996-08-02 Utgangsmaterialer for fremstilling av trans-6-£2-(substituert-pyrrol-yl)alkyl|pyran-2-on-inhibitorer for kolesterolsyntese

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15843988A 1988-02-22 1988-02-22
US158,439 1988-02-22
US303,733 1989-02-01
US07/303,733 US5003080A (en) 1988-02-22 1989-02-01 Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Publications (2)

Publication Number Publication Date
WO1989007598A2 WO1989007598A2 (fr) 1989-08-24
WO1989007598A3 true WO1989007598A3 (fr) 1989-11-02

Family

ID=26855024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/000719 WO1989007598A2 (fr) 1988-02-22 1989-02-22 Procede ameliore de preparation d'inhibiteurs trans-6-[2-(pyrrol substitue-1-yl)alkyle]pyran-2-one de synthese de cholesterol

Country Status (16)

Country Link
US (1) US5003080A (fr)
EP (2) EP0448552A1 (fr)
JP (2) JP2843627B2 (fr)
KR (1) KR970011578B1 (fr)
AT (1) ATE109777T1 (fr)
AU (2) AU634689B2 (fr)
CA (1) CA1330441C (fr)
DE (1) DE68917336T2 (fr)
DK (1) DK175135B1 (fr)
ES (1) ES2058356T3 (fr)
FI (2) FI94958C (fr)
HK (1) HK1000732A1 (fr)
IE (1) IE63994B1 (fr)
NZ (1) NZ228050A (fr)
PT (1) PT89774B (fr)
WO (1) WO1989007598A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40667E1 (en) 1989-07-21 2009-03-17 Warner-Lambert Company Llc [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
JP3171931B2 (ja) * 1992-06-02 2001-06-04 高砂香料工業株式会社 （Ｒ）−（−）−４−シアノ−３−ヒドロキシ酪酸ｔ−ブチルエステル及びその製造方法
JP3076154B2 (ja) 1992-08-13 2000-08-14 高砂香料工業株式会社 （３ｒ，５ｓ）−３，５，６−トリヒドロキシヘキサン酸誘導体及びその製造方法
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GB9512837D0 (en) * 1995-06-23 1995-08-23 Zeneca Ltd reduction of ketone groups
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
KR100681366B1 (ko) * 1997-12-19 2007-02-12 워너-램버트 익스포트 리미티드 1,3-디올의 합성방법
ES2207202T3 (es) * 1998-04-30 2004-05-16 Kaneka Corporation Procedimiento para producir derivados de acido 6-cianometil-1, 3-dioxano-4-acetico.
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (fr) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CA2391357C (fr) 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited Procede pour produire de l'atorvastatine calcique cristallin
JP2003517038A (ja) 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
US7521216B2 (en) * 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) * 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
CA2427255A1 (fr) 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolyse d'esters d'acide [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique au moyen d'hydroxyde de calcium hydroxide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
EP1728785A1 (fr) * 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
ES2558565T3 (es) * 2001-06-29 2016-02-05 Warner-Lambert Company Llc Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina)
WO2003004457A2 (fr) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Procede de preparation d'un inhibiteur
DK1404642T3 (da) 2001-07-06 2010-05-17 Basf Se Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
CN1610657A (zh) 2001-07-06 2005-04-27 西巴特殊化学品控股有限公司 制备用于合成他汀类衍生物、特别是7－氨基3,5－二羟基庚酸衍生物的中间体的方法,及其中间体
MXPA03012045A (es) 2001-07-06 2004-03-29 Teva Pharma Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
JP2005500351A (ja) 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
JP2005520792A (ja) * 2001-11-22 2005-07-14 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ピロール合成
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
KR20090045419A (ko) * 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
AU2003251523A1 (en) * 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
WO2004014896A1 (fr) * 2002-08-06 2004-02-19 Warner-Lambert Company Llc Procede de preparation de phenylamide d'acide carboxylique 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
AU2003295684A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
BRPI0409333A (pt) * 2003-04-14 2006-04-25 Warner Lambert Co processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
BRPI0409866A (pt) * 2003-05-02 2006-05-16 Dsm Ip Assests Bv processo para a preparação de (4-hidroxi-6-oxo-tetrahidropiran-2-il) acetonitrila e seus derivados
US20040242673A1 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
ES2317012T3 (es) 2003-06-18 2009-04-16 Teva Pharmaceutical Industries Limited Forma xiv cristali8na de fluvastatina sodica, sus procedimientos de preparacion, composiciones que la contienen y sus procedimientos de utilizacion.
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
WO2005012246A1 (fr) * 2003-07-25 2005-02-10 Avecia Pharmaceuticals Limited Procede et composes intermediaires servant a la preparation de statines, notamment d'atorvastatine
CA2539158A1 (fr) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Formes cristallines de l'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
WO2005026107A1 (fr) * 2003-09-18 2005-03-24 Biocon Limited Nouveau processus de preparation de tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20050159615A1 (en) * 2003-12-24 2005-07-21 Entire Interest. Process for preparation of statins with high syn to anti ratio
CN1902194B (zh) * 2003-12-29 2011-04-20 力奇制药公司 制备非晶态(4r-顺)-6-[2-[3-苯基-4-(苯基氨基甲酰基)-2-(4-氟苯基)-5-(1-甲基乙基)-吡咯-1-基]-乙基]-2,2-二甲基-[1,3]-二噁烷-4-基-乙酸的方法
CA2456430A1 (fr) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Procede ameliore pour la preparation d'atorvastatine calcique amorphe
CA2627940A1 (fr) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Procede de production d'atorvastatine calcique sous forme amorphe
AU2005232959A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
WO2005105738A2 (fr) 2004-05-05 2005-11-10 Pfizer Products Inc. Formes salines d'acide [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
CN1997651B (zh) * 2004-07-16 2012-06-06 力奇制药公司 阿托伐他汀钙的氧化降解产物
CA2672554C (fr) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
WO2006032959A2 (fr) * 2004-08-06 2006-03-30 Glenmark Pharmaceuticals Limited Procedes de preparation de derives pyrroliques
WO2006021968A1 (fr) * 2004-08-26 2006-03-02 Biocon Limited PROCESSUS DE PRÉPARATION DE 4-FLUORO-α-[2-MÉTHYL-1-OXOPROPYL]Ϝ-OXO-N-β-AMIDE DE BUTANE DE DIPHÉNYLBENZÈNE
WO2006021969A1 (fr) 2004-08-27 2006-03-02 Biocon Limited Processus pour calcium d'atorvastatine amorphe
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
EP1814541A4 (fr) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd Formulations d'atorvastatine stables
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
CA2498978A1 (fr) * 2005-02-28 2006-08-28 Apotex Pharmachem Inc. Procede ameliore de preparation de l'atorvastatine et de produits intermediaires connexes
CA2499047A1 (fr) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Methode de synthese d'un sel de semi-calcium d'atorvastatine
JP5523699B2 (ja) * 2005-04-08 2014-06-18 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
JP2009507822A (ja) * 2005-09-09 2009-02-26 ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド アトルバスタチン中間体の調製
EP1922315B1 (fr) * 2005-09-09 2009-05-27 Pfizer Science and Technology Ireland Limited Preparation d'un intermediaire de l' atorvastatine
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr) * 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
BRPI0610344A2 (pt) * 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
WO2007096751A1 (fr) * 2006-02-21 2007-08-30 Cadila Healthcare Limited Procédé de préparation d'atorvastatine calcique
KR20070116963A (ko) * 2006-03-01 2007-12-11 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미 칼슘 결정형의 제조 방법
WO2008075165A1 (fr) * 2006-12-19 2008-06-26 Pfizer Products Inc. Nouveau procédé pour la synthèse de l'acide [r-(r*, r*)]-2-(4-fluorophényl)-bêta, delta-dihydroxy-5-(1-méthyléthyl)-3-phényl-4-[(phénylamino)carbonyl]-1h-pyrrole-1-heptanoïque ou d'un sel pharmaceutiquement acceptable de celui-ci
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100881617B1 (ko) 2007-02-22 2009-02-17 (주) 성운파마코피아 아토바스타틴 제조를 위한 중간체 및 그의 제조방법
CA2679503A1 (fr) 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, acides nucleiques les codant et procedes de fabrication et d'utilisation de ceux-ci
GB0711250D0 (en) 2007-06-12 2007-07-18 Cbz Chemicals Ltd Furanose derivatives
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
KR100921195B1 (ko) * 2007-10-25 2009-10-13 주식회사 대웅제약 아토르바스타틴의 제조 방법
EP2075246A1 (fr) 2007-12-27 2009-07-01 M. J. Institute of Research Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
KR100850558B1 (ko) * 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
WO2009144736A1 (fr) * 2008-05-29 2009-12-03 Arch Pharmalabs Limited Nouveau procédé de préparation du 4-fluoro-alpha-[2-méthyl-1-oxopropyl]-gamma-oxo-n-β-diphénylbenzènebutanamide et des produits à partir de celui-ci
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
HUE025861T2 (en) 2010-09-09 2016-05-30 Dsm Sinochem Pharm Nl Bv Salts of 7-amino-3,5-dihydroxy-heptanoic acid esters
WO2012034958A1 (fr) * 2010-09-16 2012-03-22 Dsm Sinochem Pharmaceuticals Netherlands B.V. Esters d'acides hexanoïques comme intermédiaires pour la préparation d'atorvastatine
CN102127060B (zh) * 2010-12-17 2013-12-04 蚌埠丰原医药科技发展有限公司 一种阿托伐他汀钙中间体的制备方法
EP2726456A1 (fr) 2011-07-01 2014-05-07 DSM Sinochem Pharmaceuticals Netherlands B.V. Cristaux micronisés d'atorvastatine hémicalcique
US20210008084A1 (en) 2017-10-16 2021-01-14 Tsinghua University Mevalonate pathway inhibitor and pharmaceutical composition thereof
CN111909048B (zh) * 2020-09-07 2021-03-16 浙江宏元药业股份有限公司 一种多组分一锅法合成阿托伐他汀钙中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960941A (en) * 1973-04-04 1976-06-01 Ethyl Corporation 3-Hydroxy-3,4-dicarbamoylbutyric acid and salts
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40667E1 (en) 1989-07-21 2009-03-17 Warner-Lambert Company Llc [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof

Also Published As

Publication number Publication date
DE68917336D1 (de) 1994-09-15
DK197090A (da) 1990-10-04
JPH10195071A (ja) 1998-07-28
FI941550A0 (fi) 1994-04-05
NZ228050A (en) 1992-01-29
KR900700478A (ko) 1990-08-13
EP0330172B1 (fr) 1994-08-10
FI941550L (fi) 1994-04-05
JP2843627B2 (ja) 1999-01-06
AU635171B2 (en) 1993-03-11
JP3009139B2 (ja) 2000-02-14
EP0330172A3 (en) 1989-12-13
PT89774A (pt) 1989-10-04
ATE109777T1 (de) 1994-08-15
DK197090D0 (da) 1990-08-17
AU1601892A (en) 1992-07-09
FI93958B (fi) 1995-03-15
EP0330172A2 (fr) 1989-08-30
AU634689B2 (en) 1993-02-25
PT89774B (pt) 1994-03-31
ES2058356T3 (es) 1994-11-01
IE890391L (en) 1989-08-22
KR970011578B1 (en) 1997-07-12
US5003080A (en) 1991-03-26
AU1601792A (en) 1992-07-09
DK175135B1 (da) 2004-06-14
DE68917336T2 (de) 1994-12-01
CA1330441C (fr) 1994-06-28
JPH03502798A (ja) 1991-06-27
WO1989007598A2 (fr) 1989-08-24
FI94958B (fi) 1995-08-15
HK1000732A1 (en) 1998-04-24
IE63994B1 (en) 1995-06-28
FI93958C (fi) 1995-06-26
EP0448552A1 (fr) 1991-10-02
FI904118A0 (fi) 1990-08-20
FI94958C (fi) 1995-11-27

Similar Documents

Publication Publication Date Title
WO1989007598A3 (fr) Procede ameliore de preparation d'inhibiteurs trans-6-[2-(pyrrol substitue-1-yl)alkyle]pyran-2-one de synthese de cholesterol
CA2155952A1 (fr) Nouvelle methode pour la synthese de trans-6-[2-(substituant-pyrrol-1-yl)alkyl]pyran-2-ones, inhibiteurs du cholesterol
EP1466886A3 (fr) Nouveaux sels d'inhibiteurs de la HMG-CoA reductase
EP0179559A3 (fr) Trans-6-[2-(pyrrol-1-yl)alkyl]-pyran-2-ones substitués inhibiteurs de la synthèse du cholestérol
WO2002055519A3 (fr) Nouveau procede pour la synthese de phenylamide d'acide de 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylique
EP0306929A3 (fr) 6-[[Pyridin-3-yl substituées]alkyl]-et alkényl]-tétrahydro-4-hydroxypyran-2-ones-inhibiteurs de biosynthèse de cholestérol
NL970034I1 (nl) Trans-6-2-(3- of 4-carbonamido-gesubstitueerd pyrrool-1-yl)alkyl!-4-hydroxypyran-2-on als remmers van cholesterolsynthese.
EP1911445A3 (fr) Formulation pharmaceutique stable comprenant un inhibiteur de HMG-COA Reductase
IL187261A0 (en) Crystals of the sodium salt of pravastatin
AU3095497A (en) New cyanoacrylic-based adhesive formulations, preparation process and applica tions
EP0283123A3 (fr) Produits intermédiaires et procédé de préparation d'inhibiteurs de réductase HMG-COA
EP0286330A3 (fr) Substance FR-900848 et sa préparation
Butler et al. Process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl) pyran-2-one inhibitors of cholesterol synthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU DE DK FI GB JP KR LU NL NO SE US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU DE DK FI GB JP KR LU NL NO SE US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989903348

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 904118

Country of ref document: FI

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1989903348

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989903348

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 941550

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 941550

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 904118

Country of ref document: FI